Dexamethasone, dexamethasone + remdesivir in treating moderate to severe COVID-19 : retrospective observational cohort study
Copyright (c) 2023 Nithish Sattoju, Santosh Gattu, Sai Sashank Merugu, Vydhika Anneboina, Sai Ram Ganapaka..
INTRODUCTION: The aim of this study was to demonstrate the purpose of adding antiviral (remdesivir) to the existing steroidal (dexamethasone) therapy in treating coronavirus disease 2019 (COVID-19).
METHODOLOGY: A retrospective observational case cohort study was carried out to compare the effect of dexamethasone alone and in combination with remdesivir in treating moderate and severe COVID-19 disease. The patients were divided into 2 groups: Group 1 included patients treated with dexamethasone alone, and Group 2 included patients treated with dexamethasone and remdesivir. Levels of inflammatory markers (C-reactive protein, D- dimer and lactate dehydrogenase), World Health Organization (WHO) ordinal scale scoring, symptomatic improvement in terms of fever, cough, shortness of breath, 6-minutes' walk test and SpO2 levels on day of admission (D0), 3 days and 5 days after admission (D3 and D5), and 10 days overall outcome (determined as death, or discharge with or without Long Term Oxygenation Therapy) were collected and analyzed.
RESULTS: Addition of remdesivir to dexamethasone in treating COVID 19 did not have any additional benefits. No additional role of remdesivir is seen in combating the disease except in case of 10 days outcome. However, the better 10-day outcome associated with the use of remdesivir was thought to be due to the patients who were on mechanical ventilation in the dexamethasone treated group at the time of inclusion.
CONCLUSIONS: Since a similar trend was seen in both groups, our study concluded no additional role of remdesivir in combating COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of infection in developing countries - 17(2023), 7 vom: 27. Juli, Seite 953-960 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sattoju, Nithish [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3QKI37EEHE |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 31.07.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3855/jidc.17971 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360156711 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360156711 | ||
| 003 | DE-627 | ||
| 005 | 20231226082418.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3855/jidc.17971 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360156711 | ||
| 035 | |a (NLM)37515802 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sattoju, Nithish |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dexamethasone, dexamethasone + remdesivir in treating moderate to severe COVID-19 |b retrospective observational cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 31.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright (c) 2023 Nithish Sattoju, Santosh Gattu, Sai Sashank Merugu, Vydhika Anneboina, Sai Ram Ganapaka. | ||
| 520 | |a INTRODUCTION: The aim of this study was to demonstrate the purpose of adding antiviral (remdesivir) to the existing steroidal (dexamethasone) therapy in treating coronavirus disease 2019 (COVID-19) | ||
| 520 | |a METHODOLOGY: A retrospective observational case cohort study was carried out to compare the effect of dexamethasone alone and in combination with remdesivir in treating moderate and severe COVID-19 disease. The patients were divided into 2 groups: Group 1 included patients treated with dexamethasone alone, and Group 2 included patients treated with dexamethasone and remdesivir. Levels of inflammatory markers (C-reactive protein, D- dimer and lactate dehydrogenase), World Health Organization (WHO) ordinal scale scoring, symptomatic improvement in terms of fever, cough, shortness of breath, 6-minutes' walk test and SpO2 levels on day of admission (D0), 3 days and 5 days after admission (D3 and D5), and 10 days overall outcome (determined as death, or discharge with or without Long Term Oxygenation Therapy) were collected and analyzed | ||
| 520 | |a RESULTS: Addition of remdesivir to dexamethasone in treating COVID 19 did not have any additional benefits. No additional role of remdesivir is seen in combating the disease except in case of 10 days outcome. However, the better 10-day outcome associated with the use of remdesivir was thought to be due to the patients who were on mechanical ventilation in the dexamethasone treated group at the time of inclusion | ||
| 520 | |a CONCLUSIONS: Since a similar trend was seen in both groups, our study concluded no additional role of remdesivir in combating COVID-19 | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a remdesivir | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Gattu, Santosh |e verfasserin |4 aut | |
| 700 | 1 | |a Merugu, Sai Sashank |e verfasserin |4 aut | |
| 700 | 1 | |a Anneboina, Vydhika |e verfasserin |4 aut | |
| 700 | 1 | |a Ganapaka, Sai Ram |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection in developing countries |d 2007 |g 17(2023), 7 vom: 27. Juli, Seite 953-960 |w (DE-627)NLM191178497 |x 1972-2680 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:7 |g day:27 |g month:07 |g pages:953-960 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3855/jidc.17971 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 7 |b 27 |c 07 |h 953-960 | ||